Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer.

Docetaxel, one of the most effective anticancer drugs for gastric cancer, targets beta-tubulin, the major protein in mitotic spindles. Eight isotypes of beta-tubulin, with tissue and organ-specific expression, have been identified in mammalian cells. We examined class III beta-tubulin expression in gastric cancer and assessed its relationship with sensitivity to docetaxel-based chemotherapy. A total of 115 paraffin-embedded gastric tumors were analyzed by immunohistochemistry for class III beta-tubulin expression. Twenty patients with advanced gastric cancer received preoperative docetaxel-based chemotherapy. Their biopsied specimens, obtained by endoscopy before chemotherapy were examined for class III beta-tubulin expression. The relationship between expression and chemosensitivity was assessed. Forty-two (36.4%) of 115 cases were confirmed to be positive for class III beta-tubulin expression. There was no association between clinicopathological status and prognosis. Among the patients positive for class III beta-tubulin expression, only 16.7% showed no response to chemotherapy, while 64.3% responded to the chemotherapy in the negative group. Our results suggest that class III beta-tubulin is a simple and useful predictive marker for the clinical response to docetaxel-based chemotherapy in gastric cancer.

[1]  J Parness,et al.  Taxol binds to polymerized tubulin in vitro , 1981, The Journal of cell biology.

[2]  M. Lee,et al.  Five mouse tubulin isotypes and their regulated expression during development , 1985, The Journal of cell biology.

[3]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[4]  W. Mellado,et al.  Taxol: mechanisms of action and resistance. , 1986, Annals of the New York Academy of Sciences.

[5]  Y. Cheng,et al.  Metabolism and mechanism of action of 5-fluorouracil. , 1990, Pharmacology & therapeutics.

[6]  C. Fairchild,et al.  Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. , 1994, Cancer research.

[7]  D. Housman,et al.  p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.

[8]  D. Panda,et al.  Microtubule dynamics in vitro are regulated by the tubulin isotype composition. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Pyrhönen,et al.  Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. , 1995, British Journal of Cancer.

[10]  S. Lippard,et al.  Cisplatin and DNA repair in cancer chemotherapy. , 1995, Trends in biochemical sciences.

[11]  L. Peters,et al.  Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. , 1996, Journal of the National Cancer Institute.

[12]  K. Tew,et al.  Increase of βIII- and βIVa-Tubulin Isotypes in Human Prostate Carcinoma Cells as a Result of Estramustine Resistance , 1996 .

[13]  R. Luduena,et al.  Phosphorylation of III -Tubulin , 1996 .

[14]  U. Haglund,et al.  Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  M. Kavallaris,et al.  Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. , 1997, The Journal of clinical investigation.

[16]  G. Hudes,et al.  Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. , 1998, British Journal of Cancer.

[17]  G. Hudes,et al.  Cloning and sequencing of human betaIII-tubulin cDNA: induction of betaIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents. , 1998, Biochimica et biophysica acta.

[18]  C. Dumontet,et al.  Differentiation of human colon cancer cells changes the expression of β-tubulin isotypes and MAPs , 1999, British Journal of Cancer.

[19]  M. Kavallaris,et al.  Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol , 1999, British Journal of Cancer.

[20]  F. Cavalli,et al.  Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  P. Beaune,et al.  p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  T. Iwamura,et al.  Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. , 2001, The Journal of surgical research.

[23]  Y. Miyoshi,et al.  Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer , 2001, International journal of cancer.

[24]  A. Banerjee.  Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells. , 2002, Biochemical and biophysical research communications.

[25]  P. Shen,et al.  Conservation of the Class I -Tubulin Gene in Human Populations and Lack of Mutations in Lung Cancers and Paclitaxel-resistant Ovarian Cancers 1 , 2002 .

[26]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[27]  V. Mandys,et al.  Expression of class III beta-tubulin in neuroendocrine tumours of gastrointestinal tract. , 2002, Folia histochemica et cytobiologica.

[28]  D. Hixson,et al.  Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure , 2002, Cellular and Molecular Life Sciences CMLS.

[29]  S. Temam,et al.  Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck , 2002, British Journal of Cancer.

[30]  H. Nakagomi,et al.  Mutation of the class I beta-tubulin gene does not predict response to paclitaxel for breast cancer. , 2003, Cancer letters.

[31]  M. Yano,et al.  Absence of beta-tubulin gene mutation in gastric carcinoma , 2003, Gastric Cancer.

[32]  J. Ajani,et al.  Docetaxel-based chemotherapy in the treatment of gastric cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  M. Monden,et al.  Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  T. Mitsudomi,et al.  Analysis of β-tubulin gene alteration in human lung cancer cell lines , 2003 .

[35]  A. Ohtsu.  Current status and future prospects of chemotherapy for metastatic gastric cancer: a review , 2005, Gastric Cancer.

[36]  A. Frankfurter,et al.  Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. , 2005, Bulletin du cancer.